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TranscornealAbstract The purpose of the present study was to evaluate aceclofenac eye drop through excised
goat cornea. Raising pH of the formulation from 6.0 to 8.0, effect of different preservatives or effect
of viscosity enhancer decreases apparent permeability coefﬁcient. Topical ophthalmic NSAID are
used to treat ocular surface and anterior segment inﬂammation as well as post operative manage-
ment of pain and inﬂammation. Aceclofenac’s unique chemical structure makes it both a potent anti
inﬂammatory drug and lipophilic molecule that penetrates ocular tissue, ensuring relief of pain in
cataract and refractive surgery and corneal abrasion. The octanol/water partition coefﬁcient of ace-
clofenac drug is 1.86 ± 0.75. Permeation characteristics of the drug were evaluated by putting 1 ml
formulation on freshly excised goat cornea ﬁxed between donor and receptor compartments of an
all-glass modiﬁed Franz diffusion cell and measuring the drug permeated in the receptor by spec-
trophotometry at 275 nm, after 120 min. The results suggest that aceclofenac ophthalmic solution
(pH 7) containing BAC provides increased in vitro ocular availability through goat corneas. The
combination of methyl paraben and propyl paraben MP–PP preservative in aceclofenac ophthalmic
eye drop 0.1% formulated in phosphate buffer increases transcorneal permeation. The developed
formulations were evaluated for their pharmacodynamics in albino rabbits, by measuring in-vivo
study and were compared to a marketed voltrane ophthalmic solution.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University.1. Introduction
The cornea is a transparent tissue in the eye that is depend-
able for the refraction of the incoming light and is a multi-
layered tissue made up of three major cell layers: the
epithelium, the stroma, and the endothelium. A corneal epi-
thelium is a stratiﬁed cell membrane and its apical tight
junctions between surface epithelial cells are considered to
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corneal stroma is a hydrated ﬁbrous tissue with dispersed
cells and it has a hydrophilic environment limiting the pen-
etration of highly lipophilic compounds. A corneal endothe-
lium is a monolayer of cells with large intercellular
junctions, which presents a leaky lipophilic barrier. Due to
the dual nature of the cornea, with a lipophilic epithelium
and a hydrophilic stroma, the epithelium appears to be rate
limiting to the movement of hydrophilic compounds,
whereas for lipophilic compounds, the stroma is rate limiting
(Ghate et al., 2006) Topical delivery into the conjuctival cul-
de sac is by far the most common route of ocular drug
delivery. Absorption from this site may be corneal or non
corneal. The corneal absorption represents the major mech-
anism of absorption for most therapeutic entities. The cor-
nea is a trilaminate structure consisting of three major
diffusional barriers, the epithelium, stroma and endothelium
(Prausnitz and Noonan, 1998; Mitra, 2003). There are two
general processes of drug absorption across barrier mem-
branes (Grass and Robinson, 1988; Grass et al., 2006).
The ﬁrst type is called ‘‘the transcellular transport process,’’
where drug molecules have to go through the barrier cells to
reach the circulation. Transcellular transport is typically a
two step process, starting with drug uptake into the cells,
and ending with drug efﬂux out of the cells. The second
type is called ‘‘the paracellular transport process,’’ where
the drug molecules travel between the cells (or in the gaps)
to reach the circulation (Prausnitz and Noonan, 1998). The
mechanism of transcellular transport includes simple diffu-
sion, facilitated diffusion, active transport, endocytosis and
exocytosis (Shivali et al., 2011).
Aceclofenac possesses better analgesic, antipyretic and anti-
inﬂammatory efﬁcacy than diclofenac and other NSAIDs
which are frequently used for clinical therapy of arthritis, pain
and inﬂammation. Aceclofenac possesses better gastric toler-
ance than naproxen, diclofenac and indomethacin. Due to
the lipophilic nature of the drug it will be better absorbed by
the cornea and tissue and will show better action. Voltaren
eye drop is used to treat pain, swelling, and sensitivity to light
caused by certain eye surgeries.
NSAID (aceclofenac) is an excellent non steroidal anti-
inﬂammatory, analgesic and antipyretic drug. Eye solutions
0.1% w/v of aceclofenac are available to treat ocular inﬂam-
matory conditions. NSAID is recommended for treatment of
various pains, inﬂammatory conditions of eye, osteoarthritis,
rheumatoid arthritis etc. It acts by blocking the cyclo-oxy-
genase pathway. For treating ocular diseases, eye drops
may be used, but require frequent instillation of highly con-
centrated solutions due to rapid precorneal loss from the
eye. So, a pharmaceutical with prolonged action may be rec-
ommended. Aceclofenac eye drop is not available in the
market so in this we use a novel approach to formulate ace-
clofenac eye drop to reduce eye inﬂammation. Currently
these drugs are used topically very widely in the inhibition
of intra-operative miosis, management of post-operative
inﬂammation, treatment of seasonal allergic conjunctivitis,
prevention and treatment of cystoid macular edema and in
the control of pain after photo refractive keratectomy. NSA-
IDs have also been found to be useful in decreasing bacte-
rial colonization of contact lenses and prevent bacterial
adhesion to human corneal epithelial cells (Munish et al.,
2008).2. Material and methods
Aceclofenac, was obtained from Lupin Pune Research Park
Hydroxypropylmethylcellulose (HPMC 15 cps), polyvinyl alco-
hol PVA were obtained from SD Fine chemicals, Mumbai,
India. Methylcellulose and chitosan were obtained fromMerck
India. All preservatives were purchased from Nic Chemicals,
Cochin India. All the reagents and solvents used were of analyt-
ical grade. Eye ball of goat was transported from a local butch-
er shop to the laboratory in cold (4 C) normal saline within 1 h
of slaughtering the animal. The cornea was carefully excised
along with 2–4 mm of the surrounding scleral tissue and was
washed with cold normal saline till the washing was free from
proteins. The method of dissection of the cornea and the appa-
ratus was a modiﬁed version of the Franz diffusion cell as used
by Malhotra and Majumdar. The receptor cell had an internal
volume of 10 ml and side arm allowed sampling of receptor
ﬂuid. The donor cell was clamped onto the top of the receptor
cell. Water at 37 Cwas circulated through the water jacket sur-
rounding the receptor cell and Teﬂon coated magnetic stir bar
kept at the bottom of the receptor cell created a homogeneous
receptor volume (Malhotra and Majumdar, 1997).
2.1. Animals
Approval for the use of animals in the study was obtained
from the Banasthali University Animal Ethics Committee
(Banasthali University, Rajasthan, India, Ref. no. BU/BT/
184/11-12). New Zealand rabbits of either sex weighing
2.8–4.1 kg were used to measure the in vivo ocular irritation
test in the eye. All animals were managed in accordance
with the rules of the Animal Experiment Committee in Ban-
asthali University.
2.1.1. Measurement of surface tension
Formulation containing surfactant can emulsify corneal epi-
thelium and help in quicker partitioning of the drug in the epi-
thelium. To discover any possible relationship between the
surface tension of formulation and corneal penetration, the
surface tension of each aceclofenac ophthalmic solution con-
taining preservatives was measured by a stalagmometer.
2.1.2. Measurement of partition coefﬁcient (log P)
10 mg aceclofenac drug was added to 50 ml of n-octanol (pre
saturated with water) and was shaken and then 50 ml of dis-
tilled water (pre saturated with n-octanol) was added and the
process is continued in a mechanical shaker for 24 h. After
24 h both phases are separated. Absorbance of both the phases
was taken and the concentration in each phase was calculated
i.e. log {P= [aceclofenac]oct/[aceclofenac]H2O}. The concen-
tration of the base dissolved in n-octanol was obtained by
extrapolation from a calibration curve (0–20 lg/ml) of the base
in n-octanol at 275 nm (kmax) (Ghosh et al., 2007).
2.1.3. In-vitro transcorneal permeation studies
The whole eye ball of goat was transported from a local butch-
er shop to the laboratory in cold (4 C) normal saline within
1 h of slaughtering the animal. The cornea was carefully ex-
cised along with 2–4 mm of the surrounding scleral tissue
and was washed with cold normal saline till the washing was
Figure 1 Goat cornea.
Table 1 Effect of pH on aceclofenac transcorneal permeation
by goat cornea.
Formulation
pH
Papp cm/s \ 106 Relative
Papp
Corneal
hydration %
pH 6 3.969 ± 1.20 1.31 81.2 ± 0.45
pH 6.5 9.212 ± 0.75 0.33 80.0 ± 0.26
pH 7 13.81 ± 0.21 0.64 80.6 ± 0.34
pH 7.4 8.99 ± 0.32 0.74 79.4 ± 0.21
pH 8 7.89 ± 1.22 0.28 80.8 ± 0.76
Value are mean ± SD (N= 3).
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mounted by sandwiching the surrounding scleral tissue be-
tween clamped donor and receptor compartments of an all
glass modiﬁed Franz diffusion cell in such a way that its
epithelial surface faced the donor compartment. The area of
diffusion cell was 0.85 cm2. The receptor compartment was
ﬁlled with 11 ml of freshly prepared buffer solution. An aliquot
(1 ml) of test formulation was placed on the cornea and open-
ing of the donor compartment was sealed with a cover slip.
The receptor ﬂuid was maintained at 35 C with constant stir-
ring, using Teﬂon coated magnetic stir bead. Three ml sample
was withdrawn from receptor compartment at various time
intervals up to 120 min and was analyzed spectrophotometri-
cally at 275 nm. Each sample withdrawn was replaced with
an equal volume of buffer. Withdrawn samples were analyzed
spectrophotometrically (Varian-Cary 5000 UV–VIS-NIR) by
measuring absorbance at kmax of 275 nm. Each experiment
was continued for about 2.0 h and was performed at least in
triplicate. At the end of experiments each cornea (freed from
sclera) was weighed, soaked in 1-ml methanol, dried overnight
at 90 C and reweighed. From the difference in weights corneal
hydration was calculated.
Calculation of apparent permeability coefﬁcient.
Apparent permeability coefﬁcient was calculated using the
following equation
Papp ¼ DQ=Dt:1=ðA:C0:60Þ
where, DQ/Dt (lg/min) is the ﬂux across the corneal tissue. A is
the area of diffusion (cm2) C0 is the initial concentration of
drug in the donor compartment, and 60 is taken as the factor
to convert minute into second. The ﬂux across the cornea was
obtained from the slope of the regression line obtained from
the linear part of the curve between the amount permeated
(Q) and time (t) plot.
2.1.4. In vivo study
Twelve healthy rabbits weighing 2.5–3 kg were selected. Rab-
bits were kept under anesthesia during in vivo study using
1:1 Ketamine hydrochloride (30 mg/kg) and Xylazine hydro-
chloride (10 mg/kg) injected through IM route. Six rabbits
were given aceclofenac ophthalmic drops 0.1% and other six
rabbits marketed eye drop (voltaren ophthalmic). Aqueous
humor was drawn after 5 min, 0.5, 1, 2, 3, 4, 5, 6, 7 and 8 h
with the help of a 26 gauge needle, extra care was exercised
to avoid any irritation or lacrimation. Samples were analyzed
on HPLC (1200 series Quaternary LC, Agilent tech., USA)and results were recorded in duplicate (Deepika et al., 2007;
Martin et al., 1991; Faruk et al., 2000).
2.1.4.1. Comparison in experimental postoperative inﬂamma-
tion. Twelve healthy albino rabbits weighing 2.5–3.5 kg were se-
lected. The treatment was started with aceclofenac ophthalmic
solution after the appearance of postoperative inﬂammation fol-
lowing cataract surgery, prevention and treatment of cystoid
macular edema (CME) following cataract surgery, ocular dis-
comfort and pain following refractive surgery and intraopera-
tive miosis during cataract surgery. Six rabbits were treated
with aceclofenac ophthalmic drops (0.1 w/v) and other six were
treated with the given diclofenac sodium ophthalmic solution
0.1% (voltaren ophthalmic). Based on data from in vivo
study, aceclofenac drops were administered two drops every
two hrs (from 8 am-8 pm) for the ﬁrst two days and then two
drops every four hrs (from 8 am-8 pm) for further three days.
Two drops of the given diclofenac sodium ophthalmic solution
0.1% (voltaren ophthalmic) were administered every six hrs
(8 am-8 pm) for the ﬁrst two days and then two drops every
twelve hours (8 am, 8 pm) for further three days. Results of
the therapy were recorded by observing signs of cataract sur-
gery, ocular discomfort and pain recovery of rabbits from dis-
ease. All in vivo experiments were in accordance with
guidelines of NIH animal laboratory regulations and conducted
after approval from the ethics committee.
3. Results and discussion
3.1. Formulation of aceclofenac ophthalmic solution of different
pH
Aceclofenac drug solution of 0.02% (w/v, pH 6.0) 0.05% (w/v,
pH 6.5) and 0.1% (w/v, pH 7.0, 7.4 and 8.0) concentrations
Table 2 Effect of preservative on aceclofenac transcorneal permeation by goat cornea.
Formulation pH Papp cm/s \ 106 Relative Papp Corneal hydration % Surface tension (dyne/cm)
Normal control 9.998 ± 0.86 0.96 79.21 ± 0.84 71.02
SA 7.35 ± 0.31 0.86 78.25 ± 0.64 54.61
BAC 14.53 ± 045 0.21 79.64 ± 0.45 51.34
PMN 14.211 ± 1.64 0.54 79.25 ± 0.15 65.32
PMA 6.454 ± 0.65 0.12 80.64 ± 0.78 65.45
THM 5.23 ± 0.45 0.64 80.14 ± 0.45 64.38
EDTA 5.511 ± 0.81 0.25 81.20 ± 0.72 89.31
MP-PP 15.09 ± 0.64 0.64 80.31 ± 0.51 74.31
Value are mean ± SD (N= 3).
SA-sorbic acid, BAC-benzalkonium chloride, PMN-phenyl mercuric nitrate, PMA-phenyl mercuric acetate, THM-thiomersal, EDTA-disodium
edetate, MM-PP-methyl paraben and propyl paraben.
Table 3 Effect of viscosity enhancer on aceclofenac transcor-
neal permeation by goat cornea.
Formulation
pH
Papp cm/s \ 106 Relative
Papp
Corneal
hydration %
Normal control 12.67 ± 0.41 0.97 79.25 ± 0.46
HPMC 11.170 ± 0.85 0.54 78.25 ± 0.51
MC 5.66 ± 0.43 0.64 78.63 ± 0.25
CHITOSAN 8.716 ± 0.75 0.45 78.15 ± 0.73
PVA 5.040 ± 0.64 0.82 78.64 ± 0.61
Value are mean ± SD (N= 3).
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required quantity of aceclofenac was dissolved in 100 ml of iso-
tonic phosphate buffer pH 7.4 to have 0.05, 0.1 and 0.15% (w/
v) concentrations as shown in (Table 1).
3.2. Formulation of aceclofenac ophthalmic solutions 0.1 (w/v,
pH 7) containing preservative
Aceclofenac 0.1% (w/v) solution in isotonic phosphate buffer
pH 7 containing either benzalkonium chloride (BAC
0.01% w/v), phenyl mercuric nitrate (PMN 0.001% w/v), phe-
nyl mercuric acetate (PMA 0.001% w/v), or benzyl alcohol
(BA 0. 5% v/v) was prepared as shown in (Table 2).Effect of pH on aceclofenac tra
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Figure 2 Effect of pH on aceclofenac transcorneal perme3.3. Formulation of aceclofenac ophthalmic solutions (0.1, w/v)
containing viscosity enhancer
The drug aceclofenac 0.1% (w/v) solutions in isotonic phosphate
buffer (pH7), hydroxypropylmethylcellulose (HPMC), polyvinyl
alcohol (PVA), methyl cellulose (MC), chitosan were used. (Ta-
ble 3) shows the viscolizing effect on transcorneal preparation
of aceclofenac. The corneal permeation of aceclofenac through
goat cornea is shown in (Fig. 2) and (Table 1), the aceclofenac for-
mulation frompH6–8 results in a signiﬁcant decrease in apparent
permeability coefﬁcient. Diclofenac ophthalmic solution is com-
mercially available as 0.1% (w/v) solution. For aceclofenac
opthalmic solution higher pH may decrease the fraction union-
ized and apparent permeability coefﬁcient or by cornea contains
both positively and negatively charged groups whose magnitude
and polarity depend on the degree of protonation. At pH above
the iso-electric point (pI= 3.2), the cornea carries a net negative
charge and thereby becomes less permeable to negatively charged
species or anion (Rojanasakul andRobinson, 1989).However the
concentration of the drug in donor at lower pH reduced the
cumulative permeation. Topical application of diclofenac pro-
duces annoying sensations like burning and intense stinging
(Quintana-Hauet al., 2005).Formulations having a lower pHwill
further increase the ocular irritationpotential of aceclofenac. Per-
meation of drug from formulations of pH 6.0 and 8.0 had a lag
phase of 30 min.nscorneal permeation by goat 
nea
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 mins
ation by goat cornea. Values are mean ± S.D. (n= 3)
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Figure 4 Effect of viscosity enhancer of aceclofenac on transcorneal permeation by goat cornea.
244 V. Dave, S. PaliwalA signiﬁcant difference was observed with preservative on
corneal permeation of aceclofenac. The results shown in (Ta-
ble 2) and (Fig. 3), reveal that there was a signiﬁcant increase
(p< 0.05) in apparent permeability coefﬁcient of the drug
with the use of the combination of methyl paraben and propyl
paraben MP-PP, while there was a signiﬁcant decrease
(p< 0.05) with the use of sorbic acid (SA). The combination
of methyl paraben and propyl paraben MP-PP has been re-
ported to enhance the corneal permeation of insulin, a peptide
(Sasaki et al., 1994). The corneal hydration is between 78%
and 81%. BAC enhanced the corneal permeation. It has earlier
been reported that anionic drugs like ibuprofen, ﬂurbiprofen
and ketorolac enhance the corneal permeation. There was no
signiﬁcant change in ETDA, PMA THM and SA. The surface
tension of the formulation varied between 51.34 and
89.31 dynes/cm, indicating the presence of a surfactant as
shown in (Table 2). There was a decrease in the surface tension
of the optimized formulation, indicating the increase in corneal
permeation by corneal disruption or by emulsiﬁcation of cor-
neal epithelium due to the presence of benzalkonium chloride
BAC. Partition coefﬁcient (log P) of aceclofenac was found to
be 1.86 ± 0.75. (Table 3) and (Fig. 4) show the effect of viscos-ity enhancer on corneal permeation of aceclofenac. The results
show that there was a signiﬁcant decrease in apparent perme-
ability coefﬁcient with the use of MC and PVA as the viscosity
enhancer while the use of HPMC showed least reduction in
apparent permeability coefﬁcient compared with normal
controls. Chitosan gave lesser permeability than HPMC. The
use of viscosity enhancer was associated with the increase in
lag times because of slower diffusion of the drug from viscous
solutions. It is generally believed that the inclusion of a viscos-
ity-increasing agent in an ophthalmic solution will increase
ocular bioavailability by prolonging contact time of the drug
in the eye. In all the formulations the corneal hydration is be-
tween 75% and 80%, indicating no corneal damage.
3.3.1. In vivo study
Both groups of rabbits showed the same pattern of recovery
from postoperative inﬂammation following cataract surgery,
ocular discomfort and pain. Aceclofenac opthalmic eye drop
preparation showed comparatively better cure to signs and
symptoms of treatment of postoperative inﬂammation follow-
ing cataract surgery, ocular discomfort and pain with less fre-
quent administration thus reducing toxic accumulation of the
In-vivo study of different Eye drops 
0
10
20
30
40
50
60
70
0 10 20 30 40 50
Time in mins 
A
qu
eo
us
 H
um
or
 C
on
ce
nt
ra
tio
n
Voltaren ophthalmic®
Aceclofenac Opthalimic drop
0.1% w ith BAC
Aceclofenac Opthalimic drop
0.1% w ith HPMC
Figure 5 In-vivo study of eye drop.
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dium ophthalmic solution 0.1% (voltaren ophthalmic) thus
enhancing compliance by less frequent administration. As
shown in (Fig. 5), after treatment aqueous humor was col-
lected using a 26-gauge syringe and incubated on agar to see
the presence of any organism and the colony count was normal
when compared to incubated aqueous humor of another
healthy albino rabbit. This shows that both groups received
appropriate treatment and no further infection was found.
The rabbits were monitored after the treatment by aceclofenac
eye drop to check any signs of irritancy or inﬂammation i.e.
redness or increased tear production for 6 months. There were
no signs of irritancy or damage to the cornea of rabbit’s eyes.
It can be predicted that aceclofena eye drop is not an irritant to
the eye but still needs further studies to determine the mini-
mum toxic concentration of this new formulation. So the result
shows that the aceclofenac ophthalmic drop 0.1% with BAC is
better than market voltaren ophthalmic drop.
4. Conclusion
It can be concluded from the present studies that an increase in
the concentration of aceclofenac ophthalmic drop showed
comparatively better cure to signs and symptoms of postoper-
ative inﬂammation following cataract surgery increase in tran-
scorneal permeation. Increasing the ph of the formulation
from 6.0 to 8.0 and addition of viscosity enhancer to aceclofe-
nac ophthalmic eye drop formulated in phosphate buffer, re-
duce in apparent permeability coefﬁcient of drug through
goat cornea. As a viscosity enhancer HPMC showed least
reduction in an apparent permeability coefﬁcient compared
with normal controls. Chitosan gave lesser permeability than
HPMC. The combination of methyl paraben and propyl para-ben MM-PP preservative and benzalkonium chloride BAC in
aceclofenac ophthalmic eye drop formulated in phosphate buf-
fer increases transcorneal permeation. In-vivo study result
shows that the aceclofenac ophthalmic drop 0.1% with BAC
is better than market voltaren ophthalmic drop. Such formula-
tions offer a more intensive treatment of pain and inﬂamma-
tion, a decrease in the number of applications per day and a
better patient compliance.
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